Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pediatrics
Volume 2018 (2018), Article ID 5412138, 3 pages
Case Report

Long-Term Consequences of Fetal Angiotensin II Receptor Antagonist Exposure

Department of Pediatrics II, Neonatology and Neonatal Intensive Care Unit, Medical University of Innsbruck, Innsbruck, Austria

Correspondence should be addressed to K. Wegleiter

Received 29 August 2017; Accepted 27 November 2017; Published 11 January 2018

Academic Editor: Ozgur Cogulu

Copyright © 2018 K. Wegleiter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Fetal angiotensin II receptor antagonist exposure is associated with major complications and even death when administered during pregnancy. Neonates frequently require intensive care treatment, and mortality is high. Despite this well-known risk potential, a considerable number of women still receive angiotensin II receptor antagonists during pregnancy to treat arterial hypertension. Although clinical symptoms in the neonatal period are well described, few reports address long-term follow-up after fetal exposure to angiotensin II receptor antagonists. We here report on a patient who was unwittingly exposed to olmesartan medoxomil during pregnancy. After birth, the neonate presented with mild clinical symptoms, mainly affecting the kidneys. However, neurodevelopmental follow-up revealed a delay in motor development with muscular hypotonia and failure to thrive at age 2 years. This case highlights the fact that, despite not causing neurological symptoms in the neonatal period, fetal angiotensin II receptor antagonist exposure during pregnancy might lead to neurodevelopmental impairment in later life.